{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:44:47Z","timestamp":1777700687583,"version":"3.51.4"},"reference-count":159,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bando Grandi Attrezzature 2024","award":["B13C25001000007"],"award-info":[{"award-number":["B13C25001000007"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Extracellular vesicles (EVs) are small nanometric particles surrounded by a lipid bilayer and actively secreted by different cell types. EVs play a key role in cell-to-cell communication, and the vast array of biomolecules that EVs transport reflects the molecular profile of the originating cells. In cancer, EVs are key components of the tumor microenvironment (TME); meanwhile once released into the peripheral circulation, EVs can travel systemically and transmit signals beyond the primary tumor site, making EVs ideal candidates for liquid biopsy. Notably, EVs can be isolated from a blood sample and analyzed to obtain real-time information on tumor biology, enabling early diagnosis, monitoring of treatment response, and evaluation of disease evolution, with high sensitivity and specificity. This review examines the biological significance and clinical utility of EVs expressing the stemness-associated glycoproteins CD44 and CD133 in gastrointestinal (GI) malignancies. Cancer stem cells (CSCs) expressing these surface markers are known to exhibit enhanced tumorigenic potential, metastatic capacity, and therapy resistance. In particular, we focus on the increasing evidence that EVs enriched in CD44+ and CD133+ populations play critical roles in key aspects of tumor progression in cholangiocarcinoma, pancreatic, colorectal, and gastric cancers. Following internalization by recipient cells, CD44+ and CD133+ EVs drive phenotypic reprogramming, foster more aggressive cellular states, and promote chemoresistance by delivering specific molecular cargo. Mechanistically, CD44 isoforms, particularly CD44v6 and CD44v9, activate key oncogenic signaling pathways, including Wnt\/\u03b2-catenin and phosphoinositide 3-kinase (PI3K)\/serine\/threonine kinase AKT (AKT). In parallel, CD133-enriched EVs help maintain stemness and contribute to TME reorganization, thereby facilitating tumor progression. Despite ongoing challenges in EV isolation and standardization, EVs positive for stemness markers show great potential as liquid biopsy analytes for noninvasive disease monitoring, prognostic evaluation, and patient stratification. This review summarizes the expanding body of knowledge on cancer stem cell (CSC)-derived EVs in GI tumors, underscoring the potential of these particles for early diagnosis, prognosis, and the development of targeted therapies to overcome treatment resistance.<\/jats:p>","DOI":"10.31083\/fbl46312","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:29:27Z","timestamp":1777454967000},"source":"Crossref","is-referenced-by-count":0,"title":["CD44+ and CD133+ Extracellular Vesicles as Future Potential Targets in Gastrointestinal Tumor"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0392-4467","authenticated-orcid":true,"given":"Cristina","family":"Pizzulli","sequence":"first","affiliation":[{"name":"Department of Biosciences, Biotechnology and Environment, University of Bari, 70121 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6377-7655","authenticated-orcid":true,"given":"Beatrice","family":"Menicacci","sequence":"additional","affiliation":[{"name":"Department of Health Science, University of Florence, 50139 Florence, Italy"},{"name":"Pancreas Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3698-4642","authenticated-orcid":true,"given":"Margherita","family":"Parrini","sequence":"additional","affiliation":[{"name":"Department of Health Science, University of Florence, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5462-3050","authenticated-orcid":true,"given":"Edoardo","family":"Tonelli","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8581-4566","authenticated-orcid":true,"given":"Caterina","family":"Bartolini","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3745-5997","authenticated-orcid":true,"given":"Armando","family":"Curto","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0558-5322","authenticated-orcid":true,"given":"Giulia","family":"Petroni","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8861-8718","authenticated-orcid":true,"given":"Serena","family":"Pillozzi","sequence":"additional","affiliation":[{"name":"Pancreas Unit, Careggi University Hospital, 50134 Florence, Italy"},{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5416-6290","authenticated-orcid":true,"given":"Andrea","family":"Galli","sequence":"additional","affiliation":[{"name":"Pancreas Unit, Careggi University Hospital, 50134 Florence, Italy"},{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Sun YZ, Ruan JS, Jiang ZS, Wang L, Wang SM. Extracellular Vesicles: A New Perspective in Tumor Therapy. BioMed Research International. 2018; 2018: 2687954.","DOI":"10.1155\/2018\/2687954"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Bebelman MP, Smit MJ, Pegtel DM, Baglio SR. Biogenesis and function of extracellular vesicles in cancer. Pharmacology & Therapeutics. 2018; 188: 1\u201311.","DOI":"10.1016\/j.pharmthera.2018.02.013"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Hu T, Wolfram J, Srivastava S. Extracellular Vesicles in Cancer Detection: Hopes and Hypes. Trends in Cancer. 2021; 7: 122\u2013133.","DOI":"10.1016\/j.trecan.2020.09.003"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Sun H, Burrola S, Wu J, Ding WQ. Extracellular Vesicles in the Development of Cancer Therapeutics. International Journal of Molecular Sciences. 2020; 21: 6097.","DOI":"10.3390\/ijms21176097"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Yu J, Sane S, Kim JE, Yun S, Kim HJ, Jo KB, et al. Biogenesis and delivery of extracellular vesicles: harnessing the power of EVs for diagnostics and therapeutics. Frontiers in Molecular Biosciences. 2024; 10: 1330400.","DOI":"10.3389\/fmolb.2023.1330400"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"van Niel G, Carter DRF, Clayton A, Lambert DW, Raposo G, Vader P. Challenges and directions in studying cell-cell communication by extracellular vesicles. Nature Reviews. Molecular Cell Biology. 2022; 23: 369\u2013382.","DOI":"10.1038\/s41580-022-00460-3"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Li Y, Meng L, Li B, Li Y, Shen T, Zhao B. The Exosome Journey: From Biogenesis to Regulation and Function in Cancers. Journal of Oncology. 2022; 2022: 9356807.","DOI":"10.1155\/2022\/9356807"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Raiborg C, Stenmark H. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature. 2009; 458: 445\u2013452.","DOI":"10.1038\/nature07961"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Han QF, Li WJ, Hu KS, Gao J, Zhai WL, Yang JH, et al. Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. Molecular Cancer. 2022; 21: 207.","DOI":"10.1186\/s12943-022-01671-0"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Mayran N, Parton RG, Gruenberg J. Annexin II regulates multivesicular endosome biogenesis in the degradation pathway of animal cells. The EMBO Journal. 2003; 22: 3242\u20133253.","DOI":"10.1093\/emboj\/cdg321"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Williams JK, Ngo JM, Lehman IM, Schekman R. Annexin A6 mediates calcium-dependent exosome secretion during plasma membrane repair. eLife. 2023; 12: e86556.","DOI":"10.7554\/eLife.86556"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Ortega FG, Roefs MT, de Miguel Perez D, Kooijmans SA, de Jong OG, Sluijter JP, et al. Interfering with endolysosomal trafficking enhances release of bioactive exosomes. Nanomedicine: Nanotechnology, Biology, and Medicine. 2019; 20: 102014.","DOI":"10.1016\/j.nano.2019.102014"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Machado ER, Annunziata I, van de Vlekkert D, Grosveld GC, d\u2019Azzo A. Lysosomes and Cancer Progression: A Malignant Liaison. Frontiers in Cell and Developmental Biology. 2021; 9: 642494.","DOI":"10.3389\/fcell.2021.642494"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Wang C, Telpoukhovskaia MA, Bahr BA, Chen X, Gan L. Endo-lysosomal dysfunction: a converging mechanism in neurodegenerative diseases. Current Opinion in Neurobiology. 2018; 48: 52\u201358.","DOI":"10.1016\/j.conb.2017.09.005"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Ko M, Qui\u00f1ones-Hinojosa A, Rao R. Emerging links between endosomal pH and cancer. Cancer Metastasis Reviews. 2020; 39: 519\u2013534.","DOI":"10.1007\/s10555-020-09870-1"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Dellar ER, Hill C, Melling GE, Carter DRF, Baena-Lopez LA. Unpacking extracellular vesicles: RNA cargo loading and function. Journal of Extracellular Biology. 2022; 1: e40.","DOI":"10.1002\/jex2.40"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi MJ, et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. Journal of Hematology & Oncology. 2022; 15: 83.","DOI":"10.1186\/s13045-022-01305-4"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Irmer B, Chandrabalan S, Maas L, Bleckmann A, Menck K. Extracellular Vesicles in Liquid Biopsies as Biomarkers for Solid Tumors. Cancers. 2023; 15: 1307.","DOI":"10.3390\/cancers15041307"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Yang X, Zhang Y, Zhang Y, Zhang S, Qiu L, Zhuang Z, et al. The Key Role of Exosomes on the Pre-metastatic Niche Formation in Tumors. Frontiers in Molecular Biosciences. 2021; 8: 703640.","DOI":"10.3389\/fmolb.2021.703640"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Bhatia R, Chang J, Munoz JL, Walker ND. Forging New Therapeutic Targets: Efforts of Tumor Derived Exosomes to Prepare the Pre-Metastatic Niche for Cancer Cell Dissemination and Dormancy. Biomedicines. 2023; 11: 1614.","DOI":"10.3390\/biomedicines11061614"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015; 527: 329\u2013335.","DOI":"10.1038\/nature15756"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Nyahatkar S, Kalele K. Exosomes-based liquid biopsy: An effective approach for drugs and therapeutics resistance screening in cancer. The Journal of Liquid Biopsy. 2024; 4: 100144.","DOI":"10.1016\/j.jlb.2024.100144"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduction and Targeted Therapy. 2024; 9: 336.","DOI":"10.1038\/s41392-024-02021-w"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Yee NS. Liquid Biopsy: A Biomarker-Driven Tool towards Precision Oncology. Journal of Clinical Medicine. 2020; 9: 2556.","DOI":"10.3390\/jcm9082556"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Yang K, Yi T. Tumor cell stemness in gastrointestinal cancer: regulation and targeted therapy. Frontiers in Molecular Biosciences. 2024; 10: 1297611.","DOI":"10.3389\/fmolb.2023.1297611"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Loh JJ, Ma S. Hallmarks of cancer stemness. Cell Stem Cell. 2024; 31: 617\u2013639.","DOI":"10.1016\/j.stem.2024.04.004"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Ingangi V, Minopoli M, Ragone C, Motti ML, Carriero MV. Role of Microenvironment on the Fate of Disseminating Cancer Stem Cells. Frontiers in Oncology. 2019; 9: 82.","DOI":"10.3389\/fonc.2019.00082"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Liu Y, Wang Y, Sun S, Chen Z, Xiang S, Ding Z, et al. Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside. Experimental Hematology & Oncology. 2022; 11: 97.","DOI":"10.1186\/s40164-022-00352-4"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Noh CK, Wang HJ, Kim CM, Kim J, Yoon SY, Lee GH, et al. EpCAM as a Predictive Marker of Tumor Recurrence and Survival in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma. Anticancer Research. 2018; 38: 4101\u20134109.","DOI":"10.21873\/anticanres.12700"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Zhou Y, Wang B, Wu J, Zhang C, Zhou Y, Yang X, et al. Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection. BMC Cancer. 2016; 16: 506.","DOI":"10.1186\/s12885-016-2526-4"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Wang W, Lokman NA, Barry SC, Oehler MK, Ricciardelli C. LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance. Cancer Metastasis Reviews. 2025; 44: 23.","DOI":"10.1007\/s10555-024-10239-x"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Lavudi K, Nuguri SM, Pandey P, Kokkanti RR, Wang QE. ALDH and cancer stem cells: Pathways, challenges, and future directions in targeted therapy. Life Sciences. 2024; 356: 123033.","DOI":"10.1016\/j.lfs.2024.123033"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Jahangiri L. Cancer Stem Cell Markers and Properties Across Gastrointestinal Cancers. Current Tissue Microenvironment Reports. 2023; 4: 77\u201389.","DOI":"10.1007\/s43152-023-00049-8"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Agliano A, Calvo A, Box C. The challenge of targeting cancer stem cells to halt metastasis. Seminars in Cancer Biology. 2017; 44: 25\u201342.","DOI":"10.1016\/j.semcancer.2017.03.003"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Tan F, Li X, Wang Z, Li J, Shahzad K, Zheng J. Clinical applications of stem cell-derived exosomes. Signal Transduction and Targeted Therapy. 2024; 9: 17.","DOI":"10.1038\/s41392-023-01704-0"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Chen F, Zhang K, Wang M, He Z, Yu B, Wang X, et al. VEGF-FGF Signaling Activates Quiescent CD63+ Liver Stem Cells to Proliferate and Differentiate. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 2024; 11: e2308711.","DOI":"10.1002\/advs.202308711"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Cirillo N. The Hyaluronan\/CD44 Axis: A Double-Edged Sword in Cancer. International Journal of Molecular Sciences. 2023; 24: 15812.","DOI":"10.3390\/ijms242115812"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Hassn Mesrati M, Syafruddin SE, Mohtar MA, Syahir A. CD44: A Multifunctional Mediator of Cancer Progression. Biomolecules. 2021; 11: 1850.","DOI":"10.3390\/biom11121850"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Szatanek R, Baj-Krzyworzeka M. CD44 and Tumor-Derived Extracellular Vesicles (TEVs). Possible Gateway to Cancer Metastasis. International Journal of Molecular Sciences. 2021; 22: 1463.","DOI":"10.3390\/ijms22031463"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. Journal of Hematology & Oncology. 2018; 11: 64.","DOI":"10.1186\/s13045-018-0605-5"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Sarabia-S\u00e1nchez MA, Tinajero-Rodr\u00edguez JM, Ortiz-S\u00e1nchez E, Alvarado-Ortiz E. Cancer Stem Cell markers: Symphonic masters of chemoresistance and immune evasion. Life Sciences. 2024; 355: 123015.","DOI":"10.1016\/j.lfs.2024.123015"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Xu J, Zhang H, Nie Z, He W, Zhao Y, Huang Z, et al. Cancer stem-like cells stay in a plastic state ready for tumor evolution. Neoplasia (New York, N.Y.). 2025; 61: 101134.","DOI":"10.1016\/j.neo.2025.101134"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Kesharwani P, Chadar R, Sheikh A, Rizg WY, Safhi AY. CD44-Targeted Nanocarrier for Cancer Therapy. Frontiers in Pharmacology. 2022; 12: 800481.","DOI":"10.3389\/fphar.2021.800481"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Xu H, Niu M, Yuan X, Wu K, Liu A. CD44 as a tumor biomarker and therapeutic target. Experimental Hematology & Oncology. 2020; 9: 36.","DOI":"10.1186\/s40164-020-00192-0"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase\/Akt signaling pathway. The Journal of Biological Chemistry. 2001; 276: 46024\u201346030.","DOI":"10.1074\/jbc.M105132200"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Pietras A, Katz AM, Ekstr\u00f6m EJ, Wee B, Halliday JJ, Pitter KL, et al. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell. 2014; 14: 357\u2013369.","DOI":"10.1016\/j.stem.2014.01.005"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Huang H, Huang F, Liang X, Fu Y, Cheng Z, Huang Y, et al. Afatinib Reverses EMT via Inhibiting CD44-Stat3 Axis to Promote Radiosensitivity in Nasopharyngeal Carcinoma. Pharmaceuticals (Basel, Switzerland). 2022; 16: 37.","DOI":"10.3390\/ph16010037"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Riechelmann H, Sauter A, Golze W, Hanft G, Schroen C, Hoermann K, et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncology. 2008; 44: 823\u2013829.","DOI":"10.1016\/j.oraloncology.2007.10.009"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, Coveler AL, Mahalingam D, Verheul HMW, et al. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. Oncotarget. 2016; 7: 80046\u201380058.","DOI":"10.18632\/oncotarget.11098"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Mehner LM, Munoz-Sagredo L, Sonnentag SJ, Treffert SM, Orian-Rousseau V. Targeting CD44 and other pleiotropic co-receptors as a means for broad inhibition of tumor growth and metastasis. Clinical & Experimental Metastasis. 2024; 41: 599\u2013611.","DOI":"10.1007\/s10585-024-10292-4"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Lai H, Ding X, Ye J, Deng J, Cui S. pH-responsive hyaluronic acid-based nanoparticles for targeted curcumin delivery and enhanced cancer therapy. Colloids and Surfaces. B, Biointerfaces. 2021; 198: 111455.","DOI":"10.1016\/j.colsurfb.2020.111455"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Pleska\u010d P, Fargeas CA, Veselska R, Corbeil D, Skoda J. Emerging roles of prominin-1 (CD133) in the dynamics of plasma membrane architecture and cell signaling pathways in health and disease. Cellular & Molecular Biology Letters. 2024; 29: 41.","DOI":"10.1186\/s11658-024-00554-0"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Rappa G, Fargeas CA, Le TT, Corbeil D, Lorico A. Letter to the editor: An intriguing relationship between lipid droplets, cholesterol-binding protein CD133 and Wnt\/\u03b2-catenin signaling pathway in carcinogenesis. Stem Cells (Dayton, Ohio). 2015; 33: 1366\u20131370.","DOI":"10.1002\/stem.1953"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Codini M, Garcia-Gil M, Albi E. Cholesterol and Sphingolipid Enriched Lipid Rafts as Therapeutic Targets in Cancer. International Journal of Molecular Sciences. 2021; 22: 726.","DOI":"10.3390\/ijms22020726"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clinical and Translational Medicine. 2018; 7: 18.","DOI":"10.1186\/s40169-018-0198-1"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Lehnus KS, Donovan LK, Huang X, Zhao N, Warr TJ, Pilkington GJ, et al. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells. International Journal of Oncology. 2013; 42: 1011\u20131017.","DOI":"10.3892\/ijo.2013.1787"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Pospieszna J, Dams-Kozlowska H, Udomsak W, Murias M, Kucinska M. Unmasking the Deceptive Nature of Cancer Stem Cells: The Role of CD133 in Revealing Their Secrets. International Journal of Molecular Sciences. 2023; 24: 10910.","DOI":"10.3390\/ijms241310910"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Mak AB, Schnegg C, Lai CY, Ghosh S, Yang MH, Moffat J, et al. CD133-targeted niche-dependent therapy in cancer: a multipronged approach. The American Journal of Pathology. 2014; 184: 1256\u20131262.","DOI":"10.1016\/j.ajpath.2014.01.008"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Hermansen SK, Christensen KG, Jensen SS, Kristensen BW. Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society. 2011; 59: 391\u2013407.","DOI":"10.1369\/0022155411400867"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Lu R, Zhao G, Yang Y, Jiang Z, Cai J, Hu H. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K\/AKT\/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells. Technology in Cancer Research & Treatment. 2019; 18: 1533033819864311.","DOI":"10.1177\/1533033819864311"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Yu CC, Hu FW, Yu CH, Chou MY. Targeting CD133 in the enhancement of chemosensitivity in oral squamous cell carcinoma-derived side population cancer stem cells. Head & Neck. 2016; 38 Suppl 1: E231\u2013E238.","DOI":"10.1002\/hed.23975"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Yuan Z, Liang X, Zhan Y, Wang Z, Xu J, Qiu Y, et al. Targeting CD133 reverses drug-resistance via the AKT\/NF-\u03baB\/MDR1 pathway in colorectal cancer. British Journal of Cancer. 2020; 122: 1342\u20131353.","DOI":"10.1038\/s41416-020-0783-0"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells (Dayton, Ohio). 2010; 28: 5\u201316.","DOI":"10.1002\/stem.254"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Hemati H, Kaur J, Sobti RC, Trehanpati N. Inhibition of NOTCH signaling pathway chemosensitizes HCC CD133+ cells to vincristine and 5-fluorouracil through upregulation of BBC3. Biochemical and Biophysical Research Communications. 2020; 525: 941\u2013947.","DOI":"10.1016\/j.bbrc.2020.03.009"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Waldron NN, Kaufman DS, Oh S, Inde Z, Hexum MK, Ohlfest JR, et al. Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Molecular Cancer Therapeutics. 2011; 10: 1829\u20131838.","DOI":"10.1158\/1535-7163.MCT-11-0206"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Wang Y, Chen M, Wu Z, Tong C, Dai H, Guo Y, et al. CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. Oncoimmunology. 2018; 7: e1440169.","DOI":"10.1080\/2162402X.2018.1440169"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Dai H, Tong C, Shi D, Chen M, Guo Y, Chen D, et al. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology. 2020; 9: 1846926.","DOI":"10.1080\/2162402X.2020.1846926"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Karbanov\u00e1 J, Thamm K, Fargeas CA, Deniz IA, Lorico A, Corbeil D. Prominosomes - a particular class of extracellular vesicles containing prominin-1\/CD133? Journal of Nanobiotechnology. 2025; 23: 61.","DOI":"10.1186\/s12951-025-03102-w"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Kaneko K, Liang Y, Liu Q, Zhang S, Scheiter A, Song D, et al. Identification of CD133+ intercellsomes in intercellular communication to offset intracellular signal deficit. eLife. 2023; 12: RP86824.","DOI":"10.7554\/eLife.86824"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Zhang N, Shu L, Liu Z, Shi A, Zhao L, Huang S, et al. The role of extracellular vesicles in cholangiocarcinoma tumor microenvironment. Frontiers in Pharmacology. 2024; 14: 1336685.","DOI":"10.3389\/fphar.2023.1336685"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Lapitz A, Azkargorta M, Milkiewicz P, Olaizola P, Zhuravleva E, Grimsrud MM, et al. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma. Journal of Hepatology. 2023; 79: 93\u2013108.","DOI":"10.1016\/j.jhep.2023.02.027"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Suwannakul N, Ma N, Thanan R, Pinlaor S, Ungarreevittaya P, Midorikawa K, et al. Overexpression of CD44 Variant 9: A Novel Cancer Stem Cell Marker in Human Cholangiocarcinoma in Relation to Inflammation. Mediators of Inflammation. 2018; 2018: 4867234.","DOI":"10.1155\/2018\/4867234"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Suwannakul N, Ma N, Midorikawa K, Oikawa S, Kobayashi H, He F, et al. CD44v9 Induces Stem Cell-Like Phenotypes in Human Cholangiocarcinoma. Frontiers in Cell and Developmental Biology. 2020; 8: 417.","DOI":"10.3389\/fcell.2020.00417"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Padthaisong S, Thanee M, Namwat N, Phetcharaburanin J, Klanrit P, Khuntikeo N, et al. Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma. Journal of Translational Medicine. 2020; 18: 64.","DOI":"10.1186\/s12967-020-02243-w"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Mizukami T, Kamachi H, Mitsuhashi T, Einama T, Hatanaka Y, Kamiyama T, et al. Cytoplasmic CD133 expression correlates with histologic differentiation and is a significant prognostic factor in extrahepatic bile duct cancer and gallbladder cancer. Oncology Letters. 2018; 16: 6423\u20136430.","DOI":"10.3892\/ol.2018.9499"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S, et al. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. Journal of Gastroenterology. 2010; 45: 896\u2013902.","DOI":"10.1007\/s00535-010-0235-3"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Leelawat K, Thongtawee T, Narong S, Subwongcharoen S, Treepongkaruna SA. Strong expression of CD133 is associated with increased cholangiocarcinoma progression. World Journal of Gastroenterology. 2011; 17: 1192\u20131198.","DOI":"10.3748\/wjg.v17.i9.1192"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Fan L, He F, Liu H, Zhu J, Liu Y, Yin Z, et al. CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma. BMC Cancer. 2011; 11: 320.","DOI":"10.1186\/1471-2407-11-320"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Jeong MH, Son T, Tae YK, Park CH, Lee HS, Chung MJ, et al. Plasmon-Enhanced Single Extracellular Vesicle Analysis for Cholangiocarcinoma Diagnosis. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 2023; 10: e2205148.","DOI":"10.1002\/advs.202205148"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Urban SK, S\u00e4nger H, Krawczyk M, Julich-Haertel H, Willms A, Ligocka J, et al. Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation. Liver International: Official Journal of the International Association for the Study of the Liver. 2020; 40: 3103\u20133116.","DOI":"10.1111\/liv.14585"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Julich-Haertel H, Urban SK, Krawczyk M, Willms A, Jankowski K, Patkowski W, et al. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. Journal of Hepatology. 2017; 67: 282\u2013292.","DOI":"10.1016\/j.jhep.2017.02.024"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Ikeda C, Haga H, Makino N, Inuzuka T, Kurimoto A, Ueda T, et al. Utility of Claudin-3 in extracellular vesicles from human bile as biomarkers of cholangiocarcinoma. Scientific Reports. 2021; 11: 1195.","DOI":"10.1038\/s41598-021-81023-y"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Hidalgo M, Cascinu S, Kleeff J, Labianca R, L\u00f6hr JM, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015; 15: 8\u201318.","DOI":"10.1016\/j.pan.2014.10.001"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Zhao S, Chen C, Chang K, Karnad A, Jagirdar J, Kumar AP, et al. CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2016; 22: 5592\u20135604.","DOI":"10.1158\/1078-0432.CCR-15-3115"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Ota I, Li XY, Hu Y, Weiss SJ. Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106: 20318\u201320323.","DOI":"10.1073\/pnas.0910962106"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Adhikary P, Chakrabarti J, Wang J, Ezuma-Igwe U, Sun X, Bastian WC, et al. Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal Adenocarcinoma. bioRxiv. 2025.  (preprint)","DOI":"10.1101\/2025.05.22.655586"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Ren B, Cui M, Yang G, Wang H, Feng M, You L, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Molecular Cancer. 2018; 17: 108.","DOI":"10.1186\/s12943-018-0858-1"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Sun H, Rana S, Wang Z, Zhao K, Schn\u00f6lzer M, Provaznik J, et al. The Pancreatic Cancer-Initiating Cell Marker CD44v6 Affects Transcription, Translation, and Signaling: Consequences for Exosome Composition and Delivery. Journal of Oncology. 2019; 2019: 3516973.","DOI":"10.1155\/2019\/3516973"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Salnikov AV, Liu L, Platen M, Gladkich J, Salnikova O, Ryschich E, et al. Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. PloS One. 2012; 7: e46391.","DOI":"10.1371\/journal.pone.0046391"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Ding Q, Miyazaki Y, Tsukasa K, Matsubara S, Yoshimitsu M, Takao S. CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis. Molecular Cancer. 2014; 13: 15.","DOI":"10.1186\/1476-4598-13-15"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Nomura A, Banerjee S, Chugh R, Dudeja V, Yamamoto M, Vickers SM, et al. CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. Oncotarget. 2015; 6: 8313\u20138322.","DOI":"10.18632\/oncotarget.3228"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Chen K, Li Z, Jiang P, Zhang X, Zhang Y, Jiang Y, et al. Co-expression of CD133, CD44v6 and human tissue factor is associated with metastasis and poor prognosis in pancreatic carcinoma. Oncology Reports. 2014; 32: 755\u2013763.","DOI":"10.3892\/or.2014.3245"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Mortoglou M, Lian M, Miralles F, Dart DA, Uysal-Onganer P. miR-210 Mediated Hypoxic Responses in Pancreatic Ductal Adenocarcinoma. ACS Omega. 2024; 9: 47872\u201347883.","DOI":"10.1021\/acsomega.4c08947"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Zhu Z, Ding D, Hu H, He T. Pen2\/ErbB4 signaling regulates stemness of pancreatic ductal carcinoma. Biochimica et Biophysica Acta. Molecular Basis of Disease. 2024; 1870: 167316.","DOI":"10.1016\/j.bbadis.2024.167316"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Ruivo CF, Bastos N, Adem B, Batista I, Duraes C, Melo CA, et al. Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression. Gut. 2022; 71: 324994.","DOI":"10.1136\/gutjnl-2021-324994"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Mu W, Xu Y, Gu P, Wang W, Li J, Ge Y, et al. Exosomal CD44 Cooperates with Integrin \u03b16\u03b24 to Support Organotropic Metastasis via Regulating Tumor Cell Motility and Target Host Cell Activation. Engineering. 2021; 7: 1413\u20131423.","DOI":"10.1016\/j.eng.2020.08.013"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Li X, Li K, Li M, Lin X, Mei Y, Huang X, et al. Chemoresistance Transmission via Exosome-Transferred MMP14 in Pancreatic Cancer. Frontiers in Oncology. 2022; 12: 844648.","DOI":"10.3389\/fonc.2022.844648"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Jung T, Castellana D, Klingbeil P, Cuesta Hern\u00e1ndez I, Vitacolonna M, Orlicky DJ, et al. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia (New York, N.Y.). 2009; 11: 1093\u20131105.","DOI":"10.1593\/neo.09822"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Xie Z, Gao Y, Ho C, Li L, Jin C, Wang X, et al. Exosome-delivered CD44v6\/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment. Gut. 2022; 71: 568\u2013579.","DOI":"10.1136\/gutjnl-2020-323014"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Sakaue T, Koga H, Iwamoto H, Nakamura T, Ikezono Y, Abe M, et al. Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer. Medical Molecular Morphology. 2019; 52: 198\u2013208.","DOI":"10.1007\/s00795-019-00218-5"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Fargeas CA, Karbanov\u00e1 J, Corbeil D. Assessment of CD133-positive extracellular membrane vesicles in pancreatic cancer ascites and beyond. Medical Molecular Morphology. 2020; 53: 60\u201362.","DOI":"10.1007\/s00795-019-00221-w"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Bakhsh T, Alhazmi S, Farsi A, Yusuf AS, Alharthi A, Qahl SH, et al. Molecular detection of exosomal miRNAs of blood serum for prognosis of colorectal cancer. Scientific Reports. 2024; 14: 8902.","DOI":"10.1038\/s41598-024-58536-3"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Lenart M, Siemi\u0144ska I, Szatanek R, Mordel A, Szczepanik A, Rubinkiewicz M, et al. Identification of miRNAs Present in Cell- and Plasma-Derived Extracellular Vesicles-Possible Biomarkers of Colorectal Cancer. Cancers. 2024; 16: 2464.","DOI":"10.3390\/cancers16132464"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Li\u0219cu HD, Verga N, Atasiei DI, Badiu DC, Dumitru AV, Ultimescu F, et al. Biomarkers in Colorectal Cancer: Actual and Future Perspectives. International Journal of Molecular Sciences. 2024; 25: 11535.","DOI":"10.3390\/ijms252111535"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Zhang Q, Wang X, Liu Y, Xu H, Ye C. Pan-cancer and single-cell analyses identify CD44 as an immunotherapy response predictor and regulating macrophage polarization and tumor progression in colorectal cancer. Frontiers in Oncology. 2024; 14: 1380821.","DOI":"10.3389\/fonc.2024.1380821"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Sun J, Ye L, Shi Y, Wang X, Zhao X, Ren S, et al. MiR-6511b-5p suppresses metastasis of pMMR colorectal cancer through methylation of CD44 by directly targeting BRG1. Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2022; 24: 1940\u20131953.","DOI":"10.1007\/s12094-022-02845-4"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"Najafi S, Rahimi Z, Mansoori B, Mohammadi A, Mohammadnejad F, Amini M, et al. CD44 Suppression Improved the Chemosensitivity of HT-29 Colorectal Cancer Cells to 5-Fluorouracil and Inhibited Cell Migration. Advanced Pharmaceutical Bulletin. 2023; 13: 551\u2013562.","DOI":"10.34172\/apb.2023.053"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"You CZ, Xu H, Zhao FS, Dou J. A Validation Study of CD133 as a Reliable Marker for Identification of Colorectal Cancer Stem-Like Cells. Bulletin of Experimental Biology and Medicine. 2024; 176: 369\u2013375.","DOI":"10.1007\/s10517-024-06026-x"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Ehteram H, Aslanbeigi F, Ghoochani Khorasani E, Tolouee M, Haddad Kashani H. Expression and Prognostic Significance of Stem Cell Marker CD133 in Survival Rate of Patients with Colon Cancer. Oncology and Therapy. 2022; 10: 451\u2013461.","DOI":"10.1007\/s40487-022-00205-4"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"Sawai K, Koneri K, Kimura Y, Goi T. CD133 Expression in Circulating Tumor Cells as a Prognostic Marker in Colorectal Cancer. International Journal of Molecular Sciences. 2025; 26: 4740.","DOI":"10.3390\/ijms26104740"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Kostovski O, Jovanovikj R, Kostovska I. Co-expression of Stem Cell Markers CD133 and CD44 as Predictors of Metastatic Potential of Colorectal Carcinoma. Turkish Journal of Surgery. 2025; 41: 174\u2013179.","DOI":"10.47717\/turkjsurg.2025.6837"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Babajnai A, Rahmani S, Asadi MJ, Gheytanchi E, Adibhesami G, Vakhshiteh F, et al. Molecular and phenotypic characterization of 5-FU resistant colorectal cancer cells: toward enrichment of cancer stem cells. Cancer Cell International. 2025; 25: 154.","DOI":"10.1186\/s12935-025-03758-2"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"Wang Z, Zhao K, Hackert T, Z\u00f6ller M. CD44\/CD44v6 a Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression. Frontiers in Cell and Developmental Biology. 2018; 6: 97.","DOI":"10.3389\/fcell.2018.00097"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"Wang Z, von Au A, Schn\u00f6lzer M, Hackert T, Z\u00f6ller M. CD44v6-competent tumor exosomes promote motility, invasion and cancer-initiating cell marker expression in pancreatic and colorectal cancer cells. Oncotarget. 2016; 7: 55409\u201355436.","DOI":"10.18632\/oncotarget.10580"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"Kelemen A, Carmi I, Seress I, L\u0151rincz P, T\u00f6lgyes T, Dede K, et al. CD44 Expression Intensity Marks Colorectal Cancer Cell Subpopulations with Different Extracellular Vesicle Release Capacity. International Journal of Molecular Sciences. 2022; 23: 2180.","DOI":"10.3390\/ijms23042180"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"Suwakulsiri W, Rai A, Xu R, Chen M, Greening DW, Simpson RJ. Proteomic profiling reveals key cancer progression modulators in shed microvesicles released from isogenic human primary and metastatic colorectal cancer cell lines. Biochimica et Biophysica Acta. Proteins and Proteomics. 2019; 1867: 140171.","DOI":"10.1016\/j.bbapap.2018.11.008"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"Gao T, Wen T, Ge Y, Liu J, Yang L, Jiang Y, et al. Disruption of Core 1-mediated O-glycosylation oppositely regulates CD44 expression in human colon cancer cells and tumor-derived exosomes. Biochemical and Biophysical Research Communications. 2020; 521: 514\u2013520.","DOI":"10.1016\/j.bbrc.2019.10.149"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"Liao X, Han X, Wang Y, Yan J, Wu Z. CD133+-Derived Exosomes Carrying EIF3B Mediate Cell Metastasis and Stemness in Colorectal Cancer. Current Cancer Drug Targets. 2025.  (online ahead of print)","DOI":"10.2174\/0115680096346009250628215410"},{"key":"ref119","doi-asserted-by":"publisher","unstructured":"Sipos F, M\u0171zes G. Interconnection of CD133 Stem Cell Marker with Autophagy and Apoptosis in Colorectal Cancer. International Journal of Molecular Sciences. 2024; 25: 11201.","DOI":"10.3390\/ijms252011201"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"Yang X, Song X, Li Z, Liu N, Yan Y, Liu B. Crosstalk between extracellular vesicles and autophagy in cardiovascular pathophysiology. Pharmacological Research. 2021; 172: 105628.","DOI":"10.1016\/j.phrs.2021.105628"},{"key":"ref121","doi-asserted-by":"publisher","unstructured":"Brocco D, Simeone P, Buca D, Marino PD, De Tursi M, Grassadonia A, et al. Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer. Cancers. 2022; 14: 1357.","DOI":"10.3390\/cancers14051357"},{"key":"ref122","doi-asserted-by":"publisher","unstructured":"Asadzadeh Z, Mansoori B, Mohammadi A, Kazemi T, Mokhtarzadeh A, Shanehbandi D, et al. The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2021; 137: 111364.","DOI":"10.1016\/j.biopha.2021.111364"},{"key":"ref123","doi-asserted-by":"publisher","unstructured":"Kang M, Kim S, Ko J. Roles of CD133 in microvesicle formation and oncoprotein trafficking in colon cancer. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 2019; 33: 4248\u20134260.","DOI":"10.1096\/fj.201802018R"},{"key":"ref124","doi-asserted-by":"publisher","unstructured":"Lucchetti D, Calap\u00e0 F, Palmieri V, Fanali C, Carbone F, Papa A, et al. Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells. The American Journal of Pathology. 2017; 187: 1633\u20131647.","DOI":"10.1016\/j.ajpath.2017.03.015"},{"key":"ref125","doi-asserted-by":"publisher","unstructured":"Kim SY, Park S, Kim S, Ko J. CD133-containing microvesicles promote cancer progression by inducing M2-like tumor-associated macrophage polarization in the tumor microenvironment of colorectal cancer. Carcinogenesis. 2024; 45: 300\u2013310.","DOI":"10.1093\/carcin\/bgad093"},{"key":"ref126","doi-asserted-by":"publisher","unstructured":"Li Y, Wu M, Xu S, Huang H, Yan L, Gu Y. Colorectal cancer stem cell-derived exosomal long intergenic noncoding RNA 01315 (LINC01315) promotes proliferation, migration, and stemness of colorectal cancer cells. Bioengineered. 2022; 13: 10827\u201310842.","DOI":"10.1080\/21655979.2022.2065800"},{"key":"ref127","doi-asserted-by":"publisher","unstructured":"Chen S, Shen X. Long noncoding RNAs: functions and mechanisms in colon cancer. Molecular Cancer. 2020; 19: 167.","DOI":"10.1186\/s12943-020-01287-2"},{"key":"ref128","doi-asserted-by":"publisher","unstructured":"Watanabe T, Okumura T, Hirano K, Yamaguchi T, Sekine S, Nagata T, et al. Circulating tumor cells expressing cancer stem cell marker CD44 as a diagnostic biomarker in patients with gastric cancer. Oncology Letters. 2017; 13: 281\u2013288.","DOI":"10.3892\/ol.2016.5432"},{"key":"ref129","doi-asserted-by":"publisher","unstructured":"Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y, Uraoka N, Anami K, et al. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathology International. 2012; 62: 112\u2013119.","DOI":"10.1111\/j.1440-1827.2011.02760.x"},{"key":"ref130","doi-asserted-by":"publisher","unstructured":"Lu L, Wu M, Sun L, Li W, Fu W, Zhang X, et al. Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: A comprehensive meta-analysis with 4729 patients involved. Medicine. 2016; 95: e5163.","DOI":"10.1097\/MD.0000000000005163"},{"key":"ref131","doi-asserted-by":"publisher","unstructured":"Ibrahim HM, AbdElbary AM, Mohamed SY, Elwan A, Abdelhamid MI, Ibrahim A. Prognostic Value of Cyclin D1 and CD44 Expression in Gastric Adenocarcinoma. Journal of Gastrointestinal Cancer. 2019; 50: 370\u2013379.","DOI":"10.1007\/s12029-018-0079-2"},{"key":"ref132","unstructured":"Nosrati A, Naghshvar F, Khanari S. Cancer Stem Cell Markers CD44, CD133 in Primary Gastric Adenocarcinoma. International Journal of Molecular and Cellular Medicine. 2014; 3: 279\u2013286."},{"key":"ref133","doi-asserted-by":"publisher","unstructured":"Ahadi M, Moradi A, Musavinejad L, Movafagh A, Moradi A. The Expression of p53, CD44, Ki-67, and HER-2\/neu Markers in Gastric Cancer and Its Association with Histopathological Indicators: A Retrospective Study. Asian Pacific Journal of Cancer Prevention: APJCP. 2020; 21: 1607\u20131614.","DOI":"10.31557\/APJCP.2020.21.6.1607"},{"key":"ref134","doi-asserted-by":"publisher","unstructured":"Go SI, Ko GH, Lee WS, Lee JH, Jeong SH, Lee YJ, et al. The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer. Cancer Research and Treatment. 2019; 51: 1411\u20131419.","DOI":"10.4143\/crt.2018.663"},{"key":"ref135","doi-asserted-by":"publisher","unstructured":"Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011; 19: 387\u2013400.","DOI":"10.1016\/j.ccr.2011.01.038"},{"key":"ref136","doi-asserted-by":"publisher","unstructured":"Miyoshi S, Tsugawa H, Matsuzaki J, Hirata K, Mori H, Saya H, et al. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression. Anticancer Research. 2018; 38: 6163\u20136170.","DOI":"10.21873\/anticanres.12969"},{"key":"ref137","doi-asserted-by":"publisher","unstructured":"Jogo T, Oki E, Nakanishi R, Ando K, Nakashima Y, Kimura Y, et al. Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen spices accumulation. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2021; 24: 1089\u20131099.","DOI":"10.1007\/s10120-021-01194-5"},{"key":"ref138","doi-asserted-by":"publisher","unstructured":"Dong Y, Jin H, Zhu K, Shou C, Liu X, Zhang Q, et al. Prognostic Value of CD133 and SOX2 Expression After Neoadjuvant Chemotherapy in Patients With Locally Advanced Gastric Cancer. Asia-Pacific Journal of Clinical Oncology. 2025; 21: 425\u2013432.","DOI":"10.1111\/ajco.14160"},{"key":"ref139","doi-asserted-by":"publisher","unstructured":"Wattanawongdon W, Bathpho TS, Tongtawee T. Co-Expression of LGR5 and CD133 Cancer Stem Cell Predicts a Poor Prognosis in Patients With Gastric Cancer. The Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology. 2021; 32: 261\u2013268.","DOI":"10.5152\/tjg.2021.20108"},{"key":"ref140","doi-asserted-by":"publisher","unstructured":"Ji N, Yu JW, Ni XC, Wu JG, Wang SL, Jiang BJ. Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K\/AKT pathway. Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine. 2016; 37: 14637\u201314651.","DOI":"10.1007\/s13277-016-5319-0"},{"key":"ref141","doi-asserted-by":"publisher","unstructured":"Soleimani A, Dadjoo P, Avan A, Soleimanpour S, Rajabian M, Ferns G, et al. Emerging roles of CD133 in the treatment of gastric cancer, a novel stem cell biomarker and beyond. Life Sciences. 2022; 293: 120050.","DOI":"10.1016\/j.lfs.2021.120050"},{"key":"ref142","doi-asserted-by":"publisher","unstructured":"Li H, Wang C, Lan L, Yan L, Li W, Evans I, et al. METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability. Cellular and Molecular Life Sciences: CMLS. 2022; 79: 135.","DOI":"10.1007\/s00018-022-04129-0"},{"key":"ref143","doi-asserted-by":"publisher","unstructured":"Wang J, Zhang J, Liu H, Meng L, Gao X, Zhao Y, et al. N6-methyladenosine reader hnRNPA2B1 recognizes and stabilizes NEAT1 to confer chemoresistance in gastric cancer. Cancer Communications (London, England). 2024; 44: 469\u2013490.","DOI":"10.1002\/cac2.12534"},{"key":"ref144","doi-asserted-by":"publisher","unstructured":"Rhode P, Mehdorn M, Lyros O, Kahlert C, Kurth T, Venus T, et al. Characterization of Total RNA, CD44, FASN, and PTEN mRNAs from Extracellular Vesicles as Biomarkers in Gastric Cancer Patients. Cancers. 2021; 13: 5975.","DOI":"10.3390\/cancers13235975"},{"key":"ref145","doi-asserted-by":"publisher","unstructured":"Wang M, Yu W, Cao X, Gu H, Huang J, Wu C, et al. Exosomal CD44 Transmits Lymph Node Metastatic Capacity Between Gastric Cancer Cells via YAP-CPT1A-Mediated FAO Reprogramming. Frontiers in Oncology. 2022; 12: 860175.  Erratum in: Frontiers in Oncology. 2024; 14: 1495349.","DOI":"10.3389\/fonc.2022.860175"},{"key":"ref146","doi-asserted-by":"publisher","unstructured":"H\u00e4rk\u00f6nen K, Oikari S, Kyykallio H, Capra J, Hakkola S, Ketola K, et al. CD44s Assembles Hyaluronan Coat on Filopodia and Extracellular Vesicles and Induces Tumorigenicity of MKN74 Gastric Carcinoma Cells. Cells. 2019; 8: 276.","DOI":"10.3390\/cells8030276"},{"key":"ref147","doi-asserted-by":"publisher","unstructured":"Cabeza C, Rojas F, Lobos-Gonz\u00e1lez L, Lemaitre D, Villena J, Cordero ML, et al. Capture and detection of extracellular vesicles derived from human breast cancer cells using a 3D self-assembled nanostructured SiO2 microfluidic chip. Journal of Biological Engineering. 2025; 19: 71.","DOI":"10.1186\/s13036-025-00512-0"},{"key":"ref148","doi-asserted-by":"publisher","unstructured":"Yadav R, Singh AV, Kushwaha S, Chauhan DS. Emerging role of exosomes as a liquid biopsy tool for diagnosis, prognosis & monitoring treatment response of communicable & non-communicable diseases. The Indian Journal of Medical Research. 2024; 159: 163\u2013180.","DOI":"10.4103\/ijmr.ijmr_2344_22"},{"key":"ref149","doi-asserted-by":"publisher","unstructured":"Dilsiz N. A comprehensive review on recent advances in exosome isolation and characterization: Toward clinical applications. Translational Oncology. 2024; 50: 102121.","DOI":"10.1016\/j.tranon.2024.102121"},{"key":"ref150","doi-asserted-by":"publisher","unstructured":"Suresh PS, Zhang Q. Comprehensive Comparison of Methods for Isolation of Extracellular Vesicles from Human Plasma. Journal of Proteome Research. 2025; 24: 2956\u20132967.","DOI":"10.1021\/acs.jproteome.5c00149"},{"key":"ref151","doi-asserted-by":"publisher","unstructured":"Paget D, Checa A, Z\u00f6hrer B, Heilig R, Shanmuganathan M, Dhaliwal R, et al. Comparative and integrated analysis of plasma extracellular vesicle isolation methods in healthy volunteers and patients following myocardial infarction. Journal of Extracellular Biology. 2022; 1: e66.","DOI":"10.1002\/jex2.66"},{"key":"ref152","doi-asserted-by":"publisher","unstructured":"Li WJ, Chen H, Tong ML, Niu JJ, Zhu XZ, Lin LR. Comparison of the yield and purity of plasma exosomes extracted by ultracentrifugation, precipitation, and membrane-based approaches. Open Chemistry. 2022; 20: 182\u2013191.","DOI":"10.1515\/chem-2022-0139"},{"key":"ref153","doi-asserted-by":"publisher","unstructured":"Mizenko RR, Feaver M, Bozkurt BT, Lowe N, Nguyen B, Huang KW, et al. A critical systematic review of extracellular vesicle clinical trials. Journal of Extracellular Vesicles. 2024; 13: e12510.","DOI":"10.1002\/jev2.12510"},{"key":"ref154","doi-asserted-by":"publisher","unstructured":"Ren L, Zhang D, Pang L, Liu S. Extracellular vesicles for cancer therapy: potential, progress, and clinical challenges. Frontiers in Bioengineering and Biotechnology. 2024; 12: 1476737.","DOI":"10.3389\/fbioe.2024.1476737"},{"key":"ref155","doi-asserted-by":"publisher","unstructured":"Zemanek T, Danisovic L, Nicodemou A. Exosomes and solid cancer therapy: where are we now? Medical Oncology (Northwood, London, England). 2025; 42: 77.","DOI":"10.1007\/s12032-025-02626-3"},{"key":"ref156","doi-asserted-by":"publisher","unstructured":"Tang M, Chen Y, Li B, Sugimoto H, Yang S, Yang C, et al. Therapeutic targeting of STAT3 with small interference RNAs and antisense oligonucleotides embedded exosomes in liver fibrosis. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 2021; 35: e21557.","DOI":"10.1096\/fj.202002777RR"},{"key":"ref157","doi-asserted-by":"publisher","unstructured":"Chen H, Lin J, Shan Y, Zhengmao L. The promotion of nanoparticle delivery to two populations of gastric cancer stem cells by CD133 and CD44 antibodies. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2019; 115: 108857.","DOI":"10.1016\/j.biopha.2019.108857"},{"key":"ref158","doi-asserted-by":"publisher","unstructured":"Pei W, Zhang Y, Zhu X, Zhao C, Li X, L\u00fc H, et al. Multitargeted Immunomodulatory Therapy for Viral Myocarditis by Engineered Extracellular Vesicles. ACS Nano. 2024; 18: 2782\u20132799.","DOI":"10.1021\/acsnano.3c05847"},{"key":"ref159","doi-asserted-by":"publisher","unstructured":"Gong Z, Cheng C, Sun C, Cheng X. Harnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy. Journal of Experimental & Clinical Cancer Research: CR. 2025; 44: 138.","DOI":"10.1186\/s13046-025-03403-w"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/4\/10.31083\/FBL46312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:31:07Z","timestamp":1777455067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/4\/10.31083\/FBL46312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":159,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(25)01883-0"],"URL":"https:\/\/doi.org\/10.31083\/fbl46312","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"46312"}}